|
Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer
Yun Duk Jung, Sang Bin Lee, Yun Wha Jung, Jung Sub Song, In Sook Woo
Korean J Intern Med. 2017;32(5):923-925. Published online March 18, 2017
|
|
|
Successful desensitization of pemetrexed-induced anaphylaxis in a patient with malignant mesothelioma
Jeonghwan Youk, Hyunkyung Park, Kwang Nam Jin, Hyun Jong Moon, Min-Suk Yang, Ki Hwan Kim, Jin-Soo Kim
Korean J Intern Med. 2017;32(3):563-565. Published online November 25, 2016
|
|
|
Hemato-oncology
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2017;32(3):514-522. Published online April 14, 2017
Background/Aims: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based t..
|
|
|
Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
Junshik Hong, Sun Young Kyung, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jung, Jae-Ik Lee, Se Hoon Park, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2010;25(3):294-300. Published online August 31, 2010
Background/AimsThe efficacy and safety of pemetrexed, gefitinib, and erlotinib administration in previously treated patients with non-small cell lung cancer (NSCLC) were compared. MethodsThe study patients met the following criteria: histologica..
|
|
|
Two Lung Masses with Different Responses to Pemetrexed
Kwang Young Park, Jae Wook Jung, Seung Bum Nam, Ho Jin Lee, Hyo Seok Kim, Yoon Hee Choi, Jae Cheol Lee
Korean J Intern Med. 2010;25(2):213-216. Published online June 1, 2010
We described here a patient who had two lung masses. Although the two masses had the same histology and a similar good response to initial chemotherapy with gemcitabine and carboplatin, the response to pemetrexed as a second-line treatment was different after re-growth of the tumors. These two lu..
|
|
|
